phosphodiesterase 9

PDE5-IN-9 inhibits Phosphodiesterase PDE1c and is used to treat hypertension, heart failure, myocardial infarction, kidney failure, asthma, bronchitis, and dementia.

BAY 73-6691 racemate (Rac-BAY 73-6691) is a phosphodiesterase 9A (PDE9A) inhibitor used for research in Parkinson's disease.

Ophiobolin A is a fungal metabolite and a phytotoxin and is an effective and irreversibly inhibitor of calmodulin-activated cyclic nucleotide phosphodiesterase (IC50: 9 μM). Ophiobolin A also has antimicrobial and anticancer activity.

PDE1-IN-9 (Compound 7a) is a selective inhibitor of phosphodiesterase 1 (PDE1), targeting PDE1C with an IC50 value of 11 nM. It effectively reduces the mRNA expression of IL-1β, IL-6, TNF-α, and iNOS, while also inhibiting the production of nitric oxide (NO) and reactive oxygen species (ROS). Additionally, PDE1-IN-9 demonstrates good metabolic stability in rat liver microsomes.

ADORA2A PDE4D-IN-1 (Compound 9) is a dual inhibitor of the adenosine A2a receptor (ADORA2A) and phosphodiesterase 4D (PDE4D). This compound is applicable for research in bronchial asthma.

PF-04449613 is a phosphodiesterase 9A (PDE9A) inhibitor (IC50= 22 nM).1It is selective for PDE9A over PDE1C (IC50= >1,000 nM), as well as over a variety of other PDEs, inhibiting PDE2-8, -10, and -11 activity by less than 30% in a panel of enzymes, ion channels, and transporters at 1 μM but does inhibit the human dopamine transporter (DAT; Ki= 293 nM). PF-04449613 (0.1-100 mg kg, s.c.) increases cerebrospinal fluid (CSF) levels of cyclic GMP (cGMP) in rats. Subcutaneous administration of PF-04449613 (10 mg kg) increases the rate of dendritic spine formation and elimination in mouse primary motor cortex pyramidal neuronsin vivo.2It increases the average running speed of mice in an accelerating rotarod task, indicating improved motor learning, at the same dose. 1.Claffey, M.M., Helal, C.J., Verhoest, P.R., et al.Application of structure-based drug design and parallel chemistry to identify selective, brain penetrant, in vivo active phosphodiesterase 9A inhibitorsJ. Med. Chem.55(21)9055-9068(2012) 2.Lai, B., Li, M., Hu, A., et al.The phosphodiesterase 9 inhibitor PF-04449613 promotes dendritic spine formation and performance improvement after motor learningDev. Neurobiol.78(9)859-872(2018)

Irsenontrine (E2027) is a selective and orally active inhibitor of phosphodiesterase 9 (PDE9), primarily used for researching neurological diseases.

Irsenontrine (E2027) maleate is a selective and orally active inhibitor of phosphodiesterase 9 (PDE9). It can be utilized in the study of neurological diseases.

(R)-Irsenontrine ((R)-E2027), the R-enantiomer of Irsenontrine, is a potent inhibitor of phosphodiesterase 9 (PDE9) with an IC50 of 0.041 μM, primarily used in neurological disease research [1].

Tovinontrine (IMR-687) (IMR-687) is a potent and selective inhibitor of phosphodiesterase-9 (PDE9), designed to target sickle cell disease treatment. It exhibits high efficacy, with IC 50 values of 8.19 nM and 9.99 nM for PDE9A1 and PDE9A2, respectively [1].

Enpp-1-IN-9, a powerful inhibitor of ectonucleotide pyrophosphatase-phosphodiesterase 1 (ENPP1), exhibits wide substrate specificity, capable of cleaving various bonds such as phosphodiester bonds of nucleotides and nucleotide sugars, as well as pyrophosphate bonds of nucleotides and nucleotide sugars. Its potential application lies in the fields of cancer and infectious disease research[1].

Menabitan dihydrochloride (SP-204 dihydrochloride), the dihydrochloride salt of Menabitan, serves as a non-opioid analgesic agent by inhibiting phosphodiesterase 9 (PDE 9). Additionally, it has been shown to reduce intraocular pressure in a rabbit model .

Menabitan (SP-204) is a phosphodiesterase 9 (PDE 9) inhibitor used as a non-opioid analgesic. It has shown activity in reducing intraocular pressure in rabbit models.

Avanafil-13C-d3 the 13C and deuterated compound of Avanafil. Avanafil has a CAS number of 330784-47-9. Avanafil is a selective inhibitor of phosphodiesterase type 5 (PDE5) and is used as therapy of erectile dysfunction.